Aggressive B-Cell Lymphoma
The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.
Advertisement
Advertisement
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Cema-cel is feasible and can induce durable responses in patients with LBCL, achieving an ORR of 58% and a CR rate of 42%.
This orally available, selective inhibitor of XPO1 is the first agent of its kind to receive commercialization approval.
The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.
Expert clinicians describe which factors they consider when selecting between these two interventions for DLBCL management.
An expert panel discusses utilizing molecular strategies to determine treatment decisions for DLBCL.
In this DLBCL roundtable, experts share which novel agents or combinations they are most interested in.
Ruemu Birhiray, MD, leads an expert roundtable on the current treatment pathway in DLBCL.
The expert panel assesses the current and expected utility for clinicians of MRD in DLBCL management decisions.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Clinical evaluations of this bispecific antibody as monotherapy or in polytherapy for B-cell non-Hodgkin lymphomas continue.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Approved for adults ineligible for autologous transplant or CAR T-cell therapy following at least two systemic therapies.
Results from DALY II USA were presented during the oral abstract session on myeloma and lymphoma at the Tandem TCT Meetings.
Real-world data suggest that treatment with either axi-cel or liso-cel provides potential to sustain disease-free survival.
The trial will investigate zilovertamab vedotin in combination with R-CHP versus R-CHOP in 1,046 adult patients with DLBCL.
Dr. Cortese discusses the EPCORE NHL-2 trial of epcoritamab plus R-CHOP, the CaDAnCe-101 trial of BGB-16673, and more.
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
Tafasitamab achieved a real-world overall response rate of 73.5%, with a median duration of response of 9.6 months.
The therapies are under development for EBV-positive PTLD, non-Hodgkin lymphoma, and systemic lupus erythematosus.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.